Antitumorigenic targets of cannabinoids – current status and implications

References

• Munson AE, Harris LS, Friedman MA, et al. Antineoplastic activity of cannabinoids. J Natl Cancer Inst. 1975;55:597–602.
   PubMed Web of Science ®Google Scholar
• Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346:561–564.
   PubMed Web of Science ®Google Scholar
• Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61–65.
   PubMed Web of Science ®Google Scholar
• Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946–1949.
   PubMed Web of Science ®Google Scholar
• Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 1995;50:83–90.
   PubMed Web of Science ®Google Scholar
• Zygmunt PM, Petersson J, Andersson DA, et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 1999;400:452–457.
   PubMed Web of Science ®Google Scholar
• Bisogno T, Hanus L, De Petrocellis L, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol. 2001;134:845–852.
   PubMed Web of Science ®Google Scholar
• Deutsch DG, Chin SA. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol. 1993;46:791–796.
   PubMed Web of Science ®Google Scholar
• Saghatelian A, Trauger SA, Want EJ, et al. Assignment of endogenous substrates to enzymes by global metabolite profiling. Biochemistry. 2004;43:14332–14339.
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Melck D, Orlando P, et al. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem J. 2001;358:249–255.
   PubMed Web of Science ®Google Scholar
• De Petrocellis L, Davis JB, Di Marzo V. Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Lett. 2001;506:253–256.
   PubMed Web of Science ®Google Scholar
• De Petrocellis L, Bisogno T, Ligresti A, et al. Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems. Fundam Clin Pharmacol. 2002;16:297–302.
   PubMed Web of Science ®Google Scholar
• Fu J, Gaetani S, Oveisi F, et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature. 2003;425:90–93.
   PubMed Web of Science ®Google Scholar
• Blankman JL, Simon GM, Cravatt BF. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol. 2007;14:1347–1356.
   PubMed Web of Science ®Google Scholar
• De Petrocellis L, Melck D, Palmisano A, et al. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci U S A. 1998;95:8375–8380.
   PubMed Web of Science ®Google Scholar
• Chan PC, Sills RC, Braun AG, et al. Toxicity and carcinogenicity of delta 9-tetrahydrocannabinol in Fischer rats and B6C3F1 mice. Fundam Appl Toxicol. 1996;30:109–117.
   PubMedGoogle Scholar
• Galve-Roperh I, Sanchez C, Cortes ML, et al. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med. 2000;6:313–319.
   PubMed Web of Science ®Google Scholar
• Guzman M, Sanchez C, Galve-Roperh I. Control of the cell survival/death decision by cannabinoids. J Mol Med (Berl). 2001;78:613–625.
   PubMed Web of Science ®Google Scholar
• Gomez Del Pulgar T, Velasco G, Sanchez C, et al. De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochem J. 2002;363:183–188.
   PubMed Web of Science ®Google Scholar
• Freimuth N, Ramer R, Hinz B. Antitumorigenic effects of cannabinoids beyond apoptosis. J Pharmacol Exp Ther. 2010;332:336–344.
   PubMed Web of Science ®Google Scholar
• Ruiz L, Miguel A, Diaz-Laviada I. Delta9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism. FEBS Lett. 1999;458:400–404.
   PubMed Web of Science ®Google Scholar
• Hinz B, Ramer R, Eichele K, et al. Upregulation of cyclooxygenase-2 expression is involved in R(+)-methanandamide-induced apoptotic death of human neuroglioma cells. Mol Pharmacol. 2004;66:1643–1651.
   PubMed Web of Science ®Google Scholar
• Sanchez C, de Ceballos ML, Gomez del Pulgar T, et al. Inhibition of glioma growth in vivo by selective activation of the CB2 cannabinoid receptor. Cancer Res. 2001;61:5784–5789.
   PubMed Web of Science ®Google Scholar
• Blazquez C, Casanova ML, Planas A, et al. Inhibition of tumor angiogenesis by cannabinoids. FASEB J. 2003;17:529–531.
   PubMed Web of Science ®Google Scholar
• Ligresti A, Moriello AS, Starowicz K, et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther. 2006;318:1375–1387.
   PubMed Web of Science ®Google Scholar
• Ramer R, Heinemann K, Merkord J, et al. COX-2 and PPAR-gamma confer cannabidiol-induced apoptosis of human lung cancer cells. Mol Cancer Ther. 2013;12:69–82.
   PubMed Web of Science ®Google Scholar
• Ramer R, Merkord J, Rohde H, et al. Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1. Biochem Pharmacol. 2010;79:955–966.
   PubMed Web of Science ®Google Scholar
• Ramer R, Bublitz K, Freimuth N, et al. Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. FASEB J. 2012;26:1535–1548.
   PubMed Web of Science ®Google Scholar
• Solinas M, Massi P, Cantelmo AR, et al. Cannabidiol inhibits angiogenesis by multiple mechanisms. Br J Pharmacol. 2012;167:1218–1231.
   PubMed Web of Science ®Google Scholar
• Ramer R, Fischer S, Haustein M, et al. Cannabinoid inhibit angiogenic capacities of endothelial cells via release of tissue inhibitor of matrix metalloproteinases-1 from lung cancer cells. Biochem Pharmacol. 2014;91:202–216.
   PubMed Web of Science ®Google Scholar
• Haustein M, Ramer R, Linnebacher M, et al. Cannabinoids increase lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1. Biochem Pharmacol. 2014;92:312–325.
   PubMed Web of Science ®Google Scholar
• Holland ML, Allen JD, Arnold JC. Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1). Eur J Pharmacol. 2008;591:128–131.
   PubMed Web of Science ®Google Scholar
• Soroceanu L, Murase R, Limbad C, et al. Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target. Cancer Res. 2013;73:1559–1569.
   PubMed Web of Science ®Google Scholar
• Pineiro R, Maffucci T, Falasca M. The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene. 2011;30:142–152.
   PubMed Web of Science ®Google Scholar
• Pertwee R. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther. 1997;74:129–180.
   PubMed Web of Science ®Google Scholar
• Lauckner JE, Jensen JB, Chen HY, et al. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A. 2008;105:2699–2704.
   PubMed Web of Science ®Google Scholar
• Johns DG, Behm DJ, Walker DJ, et al. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol. 2007;152:825–831.
   PubMed Web of Science ®Google Scholar
• Ryberg E, Larsson N, Sjogren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007;152:1092–1101.
   PubMed Web of Science ®Google Scholar
• Schmuhl E, Ramer R, Salamon A, et al. Increase of mesenchymal stem cell migration by cannabidiol via activation of p42/44 MAPK. Biochem Pharmacol. 2014;87:489–501.
   PubMed Web of Science ®Google Scholar
• Andradas C, Caffarel MM, Perez-Gomez E, et al. The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. Oncogene. 2011;30:245–252.
   PubMed Web of Science ®Google Scholar
• Perez-Gomez E, Andradas C, Flores JM, et al. The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas. Oncogene. 2013;32:2534–2542.
   PubMed Web of Science ®Google Scholar
• Moreno E, Andradas C, Medrano M, et al. Targeting CB2-GPR55 receptor heteromers modulates cancer cell signaling. J Biol Chem. 2014;289:21960–21972.
   PubMed Web of Science ®Google Scholar
• Balenga NA, Martínez-Pinilla E, Kargl J, et al. Heteromerization of GPR55 and cannabinoid CB2 receptors modulates signalling. Br J Pharmacol. 2014;171:5387–5406.
   PubMed Web of Science ®Google Scholar
• Henstridge CM, Balenga NA, Ford LA, et al. The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. FASEB J. 2009;23:183–193.
   PubMed Web of Science ®Google Scholar
• Borrelli F, Pagano E, Romano B, et al. Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid. Carcinogenesis. 2014;35:2787–2797.
   PubMed Web of Science ®Google Scholar
• Sarker KP, Obara S, Nakata M, et al. Anandamide induces apoptosis of PC-12 cells: involvement of superoxide and caspase-3. FEBS Lett. 2000;472:39–44.
   PubMed Web of Science ®Google Scholar
• Bifulco M, Laezza C, Portella G, et al. Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J. 2001;15:2745–2747.
   PubMed Web of Science ®Google Scholar
• Casanova ML, Larcher F, Casanova B, et al. A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis. Cancer Res. 2002;62:3402–3407.
   PubMed Web of Science ®Google Scholar
• Casanova ML, Blazquez C, Martinez-Palacio J, et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest. 2003;111:43–50.
   PubMed Web of Science ®Google Scholar
• Nithipatikom K, Endsley MP, Isbell MA, et al. 2-arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion. Cancer Res. 2004;64:8826–8830.
   PubMed Web of Science ®Google Scholar
• McKallip RJ, Jia W, Schlomer J, et al. Cannabidiol-induced apoptosis in human leukemia cells: a novel role of cannabidiol in the regulation of p22phox and Nox4 expression. Mol Pharmacol. 2006;70:897–908.
   PubMed Web of Science ®Google Scholar
• Gustafsson K, Christensson B, Sander B, et al. Cannabinoid receptor-mediated apoptosis induced by R(+)-methanandamide and Win55,212 is associated with ceramide accumulation and p38 activation in Mantle Cell Lymphoma. Mol Pharmacol. 2006;70:1612–1620.
   PubMed Web of Science ®Google Scholar
• Carracedo A, Gironella M, Lorente M, et al. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res. 2006;66:6748–6755.
   PubMed Web of Science ®Google Scholar
• Qamri Z, Preet A, Nasser MW, et al. Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Mol Cancer Ther. 2009;8:3117–3129.
   PubMed Web of Science ®Google Scholar
• McAllister SD, Murase R, Christian RT, et al. Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res Treat. 2011;129:37–47.
   PubMed Web of Science ®Google Scholar
• Oesch S, Walter D, Wachtel M, et al. Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma. Mol Cancer Ther. 2009;8:1838–1845.
   PubMed Web of Science ®Google Scholar
• Ramer R, Hinz B. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. J Natl Cancer Inst. 2008;100:59–69.
   PubMed Web of Science ®Google Scholar
• Leelawat S, Leelawat K, Narong S, et al. The dual effects of delta(9)-tetrahydrocannabinol on cholangiocarcinoma cells: anti-invasion activity at low concentration and apoptosis induction at high concentration. Cancer Invest. 2010;28:357–363.
   PubMed Web of Science ®Google Scholar
• Patsos HA, Greenhough A, Hicks DJ, et al. The endogenous cannabinoid, anandamide, induces COX-2-dependent cell death in apoptosis-resistant colon cancer cells. Int J Oncol. 2010;37:187–193.
   PubMed Web of Science ®Google Scholar
• Xian XS, Park H, Cho YK, et al. Effect of a synthetic cannabinoid agonist on the proliferation and invasion of gastric cancer cells. J Cell Biochem. 2010;110:321–332.
   PubMed Web of Science ®Google Scholar
• Hamtiaux L, Hansoulle L, Dauguet N, et al. Increasing antiproliferative properties of endocannabinoids in N1E-115 neuroblastoma cells through inhibition of their metabolism. PloS One. 2011;6:e26823.
   PubMed Web of Science ®Google Scholar
• Pourkhalili N, Ghahremani MH, Farsandaj N, et al. Evaluation of anti-invasion effect of cannabinoids on human hepatocarcinoma cells. Toxicol Mech Methods. 2013;23:120–126.
   PubMed Web of Science ®Google Scholar
• Park SW, Kim JE, Oh SM, et al. Anticancer effects of anandamide on head and neck squamous cell carcinoma cells via the production of receptor-independent reactive oxygen species. Head Neck. 2015;37:1187–1192.
   PubMed Web of Science ®Google Scholar
• Gasperi V, Evangelista D, Oddi S, et al. Regulation of inflammation and proliferation of human bladder carcinoma cells by type-1 and type-2 cannabinoid receptors. Life Sci. 2015;138:41–51.
   PubMed Web of Science ®Google Scholar
• Blazquez C, Carracedo A, Barrado L, et al. Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J. 2006;20:2633–2635.
   PubMed Web of Science ®Google Scholar
• Jacobsson SO, Wallin T, Fowler CJ. Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J Pharmacol Exp Ther. 2001;299:951–959.
   PubMed Web of Science ®Google Scholar
• Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012;12:436–444.
   PubMed Web of Science ®Google Scholar
• Velasco G, Hernández-Tiedra S, Dávila D, et al. The use of cannabinoids as anticancer agents. Prog Neuropsychopharmacol Biol Psychiatry. 2016;64:259–266.
   PubMed Web of Science ®Google Scholar
• Salazar M, Carracedo A, Salanueva IJ, et al. Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J Clin Invest. 2009;119:1359–1372.
   PubMed Web of Science ®Google Scholar
• Salazar M, Lorente M, García-Taboada E, et al. The pseudokinase tribbles homologue-3 plays a crucial role in cannabinoid anticancer action. Biochim Biophys Acta. 2013;1831:1573–1578.
   PubMed Web of Science ®Google Scholar
• Vara D, Salazar M, Olea-Herrero N, et al. Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. Cell Death Differ. 2011;18:1099–1111.
   PubMed Web of Science ®Google Scholar
• Shrivastava A, Kuzontkoski PM, Groopman JE, et al. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross talk between apoptosis and autophagy. Mol Cancer Ther. 2011;10:1161–1172.
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182–1186.
   PubMed Web of Science ®Google Scholar
• Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer. 2006;6:449–458.
   PubMed Web of Science ®Google Scholar
• Kishimoto S, Muramatsu M, Gokoh M, et al. Endogenous cannabinoid receptor ligand induces the migration of human natural killer cells. J Biochem. 2005;137:217–223.
   PubMed Web of Science ®Google Scholar
• Maccarrone M, Attinà M, Cartoni A, et al. Gas chromatography–mass spectrometry analysis of endogenous cannabinoids in healthy and tumoral human brain and human cells in culture. J Neurochem. 2001;76:594–601.
   PubMed Web of Science ®Google Scholar
• Ligresti A, Bisogno T, Matias I, et al. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology. 2003;125:677–687.
   PubMed Web of Science ®Google Scholar
• Petersen G, Moesgaard B, Schmid PC, et al. Endocannabinoid metabolism in human glioblastomas and meningiomas compared to human non-tumour brain tissue. J Neurochem. 2005;93:299–309.
   PubMed Web of Science ®Google Scholar
• Pagotto U, Marsicano G, Fezza F, et al. Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. J Clin Endocrinol Metab. 2001;86:2687–2696.
   PubMed Web of Science ®Google Scholar
• Schmid PC, Wold LE, Krebsbach RJ, et al. Anandamide and other N-acylethanolamines in human tumors. Lipids. 2002;37:907–912.
   PubMed Web of Science ®Google Scholar
• Chen L, Chen H, Li Y, et al. Endocannabinoid and ceramide levels are altered in patients with colorectal cancer. Oncol Rep. 2015;34:447–454.
   PubMed Web of Science ®Google Scholar
• Malfitano AM, Ciaglia E, Gangemi G, et al. Update on the endocannabinoid system as an anticancer target. Expert Opin Ther Targets. 2011;15:297–308.
   PubMed Web of Science ®Google Scholar
• Sailler S, Schmitz K, Jäger E, et al. Regulation of circulating endocannabinoids associated with cancer and metastases in mice and humans. Oncoscience. 2014;1:272 282. eCollection 2014.
   PubMedGoogle Scholar
• Endsley MP, Thill R, Choudhry I, et al. Expression and function of fatty acid amide hydrolase in prostate cancer. Int J Cancer. 2008;123:1318–1326.
   PubMed Web of Science ®Google Scholar
• Thors L, Bergh A, Persson E, et al. Fatty acid amide hydrolase in prostate cancer: association with disease severity and outcome, CB1 receptor expression and regulation by IL-4. PloS One. 2010;5:e12275.
   PubMed Web of Science ®Google Scholar
• Gjerstorff MF, Benoit VM, Laenkholm AV, et al. Identification of genes with altered expression in medullary breast cancer vs. ductal breast cancer and normal breast epithelia. Int J Oncol. 2006;28:1327–1335.
   PubMed Web of Science ®Google Scholar
• Nomura DK, Long JZ, Niessen S, et al. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell. 2010;140:49–61.
   PubMed Web of Science ®Google Scholar
• Michalski CW, Oti FE, Erkan M, et al. Cannabinoids in pancreatic cancer: correlation with survival and pain. Int J Cancer. 2008;122:742–750.
   PubMed Web of Science ®Google Scholar
• Flygare J, Sander B. The endocannabinoid system in cancer – potential therapeutic target? Semin Cancer Biol. 2008;18:176–189.
   PubMed Web of Science ®Google Scholar
• Chung SC, Hammarsten P, Josefsson A. high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. Eur J Cancer. 2009;45:174–182.
   PubMed Web of Science ®Google Scholar
• Klein Nulent TJ, Van Diest PJ, Van Der Groep P, et al. Cannabinoid receptor-2 immunoreactivity is associated with survival in squamous cell carcinoma of the head and neck. Br J Oral Maxillofac Surg. 2013;1:604–609.
   Web of Science ®Google Scholar
• Messalli EM, Grauso F, Luise R, et al. Cannabinoid receptor type 1 immunoreactivity and disease severity in human epithelial ovarian tumors. Am J Obstet Gynecol. 2014;211:234.e1e6.
   PubMed Web of Science ®Google Scholar
• Jung CK, Kang WK, Park JM, et al. Expression of the cannabinoid type I receptor and prognosis following surgery in colorectal cancer. Oncol Lett. 2013;5:870–876.
   PubMed Web of Science ®Google Scholar
• Pérez-Gómez E, Andradas C, Blasco-Benito S, et al. Role of cannabinoid receptor CB2 in HER2 pro oncogenic signaling in breast cancer. J Natl Cancer Inst. 2015;107:djv077. doi:10.1093/jnci/djv077.
   PubMedGoogle Scholar
• Fowler CJ. Delta9-tetrahydrocannabinol and cannabidiol as potential curative agents for cancer: a critical examination of the preclinical literature. Clin Pharm Ther. 2015;97:587–596.
   PubMed Web of Science ®Google Scholar
• Sanchez MG, Ruiz–Llorente L, Sanchez AM, et al. Activation of phosphoinositide 3-kinase/PKB pathway by CB(1) and CB(2) cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction. Cell Signal. 2003;15:851–859.
   PubMed Web of Science ®Google Scholar
• Gardner B, Zhu LX, Sharma S, et al. Methanandamide increases COX-2 expression and tumor growth in murine lung cancer. FASEB J. 2003;17:2157–2159.
   PubMed Web of Science ®Google Scholar
• Cudaback E, Marrs W, Moeller T, et al. The expression level of CB1 and CB2 receptors determines their efficacy at inducing apoptosis in astrocytomas. PLoS One. 2010;5:e8702.
   PubMed Web of Science ®Google Scholar
• Häggström J, Cipriano M, Forshell LP, et al. Potential upstream regulators of cannabinoid receptor 1 signaling in prostate cancer: a Bayesian network analysis of data from a tissue microarray. Prostate. 2014;74:1107–1117.
   PubMed Web of Science ®Google Scholar
• Hart S, Fischer O, Ullrich A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor a-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor. Cancer Res. 2004;64:1943–1950.
   PubMed Web of Science ®Google Scholar
• Ravi J, Sneh A, Shilo K, et al. FAAH inhibition enhances anandamide mediated anti-tumorigenic effects in non-small cell lung cancer by downregulating the EGF/EGFR pathway. Oncotarget. 2014;5:2475–2486.
   PubMed Web of Science ®Google Scholar
• Sarnataro D, Pisanti S, Santoro A, et al. The cannabinoid CB1 receptor antagonist Rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism. Mol Pharmacol. 2006;70:1298–1306.
   PubMed Web of Science ®Google Scholar
• Ciaglia E, Torelli G, Pisanti S, et al. Cannabinoid receptor CB1 regulates STAT3 activity and its expression dictates the responsiveness to SR141716 treatment in human glioma patients’ cells. Oncotarget. 2015;6:15464–15481.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay B, Schuebel K, Mukhopadhyay P, et al. Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms. Hepatology. 2015 May;61:1615–1626.
   PubMed Web of Science ®Google Scholar
• Julien B, Grenard P, Teixeira-Clerc F, et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology. 2005;128:742–755.
   PubMed Web of Science ®Google Scholar
• Muñoz-Luque J, Ros J, Fernández-Varo G, et al. Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther. 2008;324:475–483.
   PubMed Web of Science ®Google Scholar
• Teixeira-Clerc F, Julien B, Grenard P, et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med. 2006;12:671–676.
   PubMed Web of Science ®Google Scholar
• Xu X, Liu Y, Huang S, et al. Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Genet Cytogenet. 2006;171:31–38.
   PubMed Web of Science ®Google Scholar
• Pourkhalili N, Ghahremani MH, Farsandaj N, et al. Evaluation of anti-invasion effect of cannabinoids on human hepatocarcinoma cells. Toxicol Mech Methods. 2013;23:120–126.
   PubMed Web of Science ®Google Scholar
• Pisanti S, Picardi P, D’Alessandro A, et al. The endocannabinoid signaling system in cancer. Trends Pharmacol Sci. 2013;34:273–282.
   PubMed Web of Science ®Google Scholar
• Larrinaga G, Begoña S, Itxaro P, et al. Cannabinoid CB1 receptor is downregulated in clear cell renal cell carcinoma. J Histochem Cytochem. 2010;58:1129–1134.
   PubMed Web of Science ®Google Scholar
• Wang D, Wang H, Ning W, et al. Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Cancer Res. 2008;68:6468–6476.
   PubMed Web of Science ®Google Scholar
• Grimsey N, Goodfellow C, Scotter E, et al. Specific detection of CB1 receptors; cannabinoid CB1 receptor antibodies are not all created equal. J Neurosci Meth. 2008;171:78–86.
   PubMed Web of Science ®Google Scholar
• Petrosino S, Di Marzo V. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr Opin Investig Drugs. 2010;11:51–62.
   PubMed Web of Science ®Google Scholar
• Ruh MF, Taylor JA, Howlett AC, et al. Failure of cannabinoid compounds to stimulate estrogen receptors. Biochem Pharmacol. 1997;53:35–41.
   PubMed Web of Science ®Google Scholar
• Jacobsson SO, Rongard E, Stridh M, et al. Serum-dependent effects of tamoxifen and cannabinoids upon C6 glioma cell viability. Biochem Pharmacol. 2000;60:1807–1813.
   PubMed Web of Science ®Google Scholar
• Mimeault M, Pommery N, Wattez N, et al. Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor downregulation and ceramide production. Prostate. 2003;56:1–12.
   PubMed Web of Science ®Google Scholar
• Laezza C, Pisanti S, Crescenzi E, et al. Anandamide inhibits Cdk2 and activates Chk1 leading to cell cycle arrest in human breast cancer cells. FEBS Lett. 2006;580:6076–6082.
   PubMed Web of Science ®Google Scholar
• Bisogno T, Melck D, De Petrocellis L, et al. Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. Biochem Biophys Res Commun. 1998;248:515–522.
   PubMed Web of Science ®Google Scholar
• Alexander JP, Cravatt BF. Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes. Chem Biol. 2005;12:1179–1187.
   PubMed Web of Science ®Google Scholar
• Bifulco M, Laezza C, Valenti M, et al. A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J. 2004;18:1606–1608.
   PubMed Web of Science ®Google Scholar
• Izzo AA, Aviello G, Petrosino S, et al. Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. J Mol Med (Berl). 2008;86:89–98.
   PubMed Web of Science ®Google Scholar
• Proto MC, Gazzerro P, Di Croce L, et al. Interaction of endocannabinoid system and steroid hormones in the control of colon cancer cell growth. J Cell Physiol. 2012;227:250–258.
   PubMed Web of Science ®Google Scholar
• Hamtiaux L, Masquelier J, Muccioli GG, et al. The association of N-palmitoylethanolamine with the FAAH inhibitor URB597 impairs melanoma growth through a supra-additive action. BMC Cancer. 2012;12:92.
   PubMed Web of Science ®Google Scholar
• Winkler K, Ramer R, Dithmer S, et al. Fatty acid amide hydrolase inhibitors confer anti-invasive and antimetastatic effects on lung cancer cells. Oncotarget. 2016 Feb 22. doi:10.18632/oncotarget.7592. [Epub ahead of print] PubMed PMID: 26930716.
   Web of Science ®Google Scholar
• Ye L, Zhang B, Seviour EG, et al. Monoacylglycerol lipase (MAGL) knockdown inhibits tumor cells growth in colorectal cancer. Cancer Lett. 2011;307:6–17.
   PubMed Web of Science ®Google Scholar
• Nomura DK, Lombardi DP, Chang JW, et al. Monoacylglycerol lipase exerts dual control over endocannabinoid and fatty acid pathways to support prostate cancer. Chem Biol. 2011;18:846–856.
   PubMed Web of Science ®Google Scholar
• Cipriano M, Gouveia-Figueira S, Persson E, et al. The influence of monoacylglycerol lipase inhibition upon the expression of epidermal growth factor receptor in human PC-3 prostate cancer cells. BMC Res Notes. 2014;7:441.
   PubMedGoogle Scholar
• Okamoto H, Yatomi Y, Ohmori T, et al. Sphingosine 1-phosphate stimulates G(i)- and Rho-mediated vascular endothelial cell spreading and migration. Thromb Res. 2000;99:259–265.
   PubMed Web of Science ®Google Scholar
• Pisanti S, Borselli C, Oliviero O, et al. Anti-invasive activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy. J Cell Physiol. 2007;211:495–503.
   PubMed Web of Science ®Google Scholar
• Kogan NM, Blazquez C, Alvarez L, et al. A cannabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells. Mol Pharmacol. 2006;70:51–59.
   PubMed Web of Science ®Google Scholar
• Thapa D, Lee JS, Heo SW, et al. Novel hexahydrocannabinol analogs as potential anti-cancer agents inhibit cell proliferation and tumor angiogenesis. Eur J Pharmacol. 2011;650:64–71.
   PubMed Web of Science ®Google Scholar
• Rajesh M, Mukhopadhyay P, Hasko G, et al. Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells. Br J Pharmacol. 2010;160:688–700.
   PubMed Web of Science ®Google Scholar
• Pisanti S, Picardi P, Prota L, et al. Genetic and pharmacologic inactivation of cannabinoid CB1 receptor inhibits angiogenesis. Blood. 2011;117:5541–5550.
   PubMed Web of Science ®Google Scholar
• Zhang X, Maor Y, Wang JF, et al. Endocannabinoid-like N-arachidonoyl serine is a novel pro-angiogenic mediator. Br J Pharmacol. 2010;160:1583–1594.
   PubMed Web of Science ®Google Scholar
• Blazquez C, Salazar M, Carracedo A, et al. Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. Cancer Res. 2008;68:1945–1952.
   PubMed Web of Science ®Google Scholar
• Preet A, Qamri Z, Nasser MW, et al. Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis. Cancer Prev Res (Phila). 2011;4:65–75.
   PubMed Web of Science ®Google Scholar
• Caffarel MM, Andradas C, Mira E, et al. Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Mol Cancer. 2010;9:196.
   PubMed Web of Science ®Google Scholar
• Preet A, Ganju RK, Groopman JE. Delta9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene. 2008;27:339–346.
   PubMed Web of Science ®Google Scholar
• Hernan Perez de la Ossa D, Lorente M, Gil-Alegre ME, et al. Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme. PloS One. 2013;8:e54795.
   PubMed Web of Science ®Google Scholar
• Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306–1309.
   PubMed Web of Science ®Google Scholar
• Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6:389–395.
   PubMed Web of Science ®Google Scholar
• Arany Z, Foo SY, Ma Y, et al. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature. 2008;451:1008–1012.
   PubMed Web of Science ®Google Scholar
• Jain RK. Molecular regulation of vessel maturation. Nat Med. 2003;9:685–693.
   PubMed Web of Science ®Google Scholar
• Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000;2:737–744.
   PubMed Web of Science ®Google Scholar
• Ahn GO, Brown JM. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell. 2008;13:193–205.
   PubMed Web of Science ®Google Scholar
• Zacchigna S, Zentilin L, Morini M, et al. AAV-mediated gene transfer of tissue inhibitor of metalloproteinases-1 inhibits vascular tumor growth and angiogenesis in vivo. Cancer Gene Ther. 2004;11:73–80.
   PubMed Web of Science ®Google Scholar
• Oh J, Seo D-W, Diaz T, et al. Tissue inhibitors of metalloproteinase 2 inhibits endothelial cell migration through increased expression of RECK. Cancer Res. 2004;64:9062–9069.
   PubMed Web of Science ®Google Scholar
• Akahane T, Akahane M, Shah A, et al. TIMP-1 inhibits microvascular endothelial cell migration by MMP-dependent and MMP-independent mechanisms. Exp Cell Res. 2004;301:158–167.
   PubMed Web of Science ®Google Scholar
• Portella G, Laezza C, Laccetti P, et al. Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J. 2003;17:1771–1773.
   PubMed Web of Science ®Google Scholar
• Blazquez C, Gonzalez-Feria L, Alvarez L, et al. Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res. 2004;64:5617–5623.
   PubMed Web of Science ®Google Scholar
• Ramer R, Hinz B. New insights into antimetastatic and anti-invasive effects of cannabinoids. Int Rev Cell Mol Biol. 2015;314:43–116.
   PubMedGoogle Scholar
• Picardi P, Ciaglia E, Proto M, et al. Anandamide inhibits breast tumor-induced angiogenesis. Transl Med UniSa. 2014;10:8–12.
   PubMedGoogle Scholar
• Cantarella G, Scollo M, Lempereur L, et al. Endocannabinoids inhibit release of nerve growth factor by inflammation-activated mast cells. Biochem Pharmacol. 2011;82:380–388.
   PubMed Web of Science ®Google Scholar
• Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature. 2005;436:518–524.
   PubMed Web of Science ®Google Scholar
• McAllister SD, Christian RT, Horowitz MP, et al. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol Cancer Ther. 2007;6:2921–2927.
   PubMed Web of Science ®Google Scholar
• Murase R, Kawamura R, Singer E, et al. Targeting multiple cannabinoid antitumor pathways with a resorcinol derivate leads to inhibition of advanced stages of breast cancer. Br J Pharmacol. 2014;171:4464–4477.
   PubMed Web of Science ®Google Scholar
• Wiley L, Beletskaya ID, Ng EW, et al Resorcinol derivatives: a novel template for the development of cannabinoid CB1/CB2 and CB2-selective agonist. J Pharmacol Exp Ther. 2002;301:679–689.
   PubMed Web of Science ®Google Scholar
• Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer. 2000;36:1621–1630.
   PubMed Web of Science ®Google Scholar
• Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol. 2000;10:415–433.
   PubMed Web of Science ®Google Scholar
• Khokha R, Waterhouse P, Yagel S, et al. Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells. Science. 1989;243:947–950.
   PubMed Web of Science ®Google Scholar
• Cattaneo M, Fontanella E, Canton C, et al. SEL1L affects human pancreatic cancer cell cycle and invasiveness through modulation of PTEN and genes related to cell-matrix interactions. Neoplasia. 2005;7:1030–1038.
   PubMed Web of Science ®Google Scholar
• Ramer R, Eichele K, Hinz B. Upregulation of tissue inhibitor of matrix metalloproteinases-1 confers the anti-invasive action of cisplatin on human cancer cells. Oncogene. 2007;26:5822–5827.
   PubMed Web of Science ®Google Scholar
• Gomez DE, Alonso DF, Yoshiji H, et al. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol. 1997;74:111–122.
   PubMed Web of Science ®Google Scholar
• Sanceau J, Truchet S, Bauvois B. Matrix metalloproteinase-9 silencing by RNA interference triggers the migratory-adhesive switch in Ewing’s sarcoma cells. J Biol Chem. 2003;278:36537–36546.
   PubMed Web of Science ®Google Scholar
• Taube ME, Liu XW, Fridman R, et al. TIMP-1 regulation of cell cycle in human breast epithelial cells via stabilization of p27(KIP1) protein. Oncogene. 2006;25:3041–3048.
   PubMed Web of Science ®Google Scholar
• Stetler-Stevenson WG. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal. 2008;1:re6.
   PubMed Web of Science ®Google Scholar
• Blázquez C, Carracedo A, Salazar M, et al. Down-regulation of tissue inhibitor of metalloproteinases-1 in gliomas: a new marker of cannabinoid antitumoral activity? Neuropharmacology. 2008;54:235–243.
   PubMed Web of Science ®Google Scholar
• Farsandaj N, Ghahremani MH, Ostad SN. Role of cannabinoid and vanilloid receptors in invasion of human breast carcinoma cells. J Environ Pathol Toxicol Oncol. 2012;31:377–387.
   PubMed Web of Science ®Google Scholar
• Coke CJ, Scarlett KA, Chetram MA, et al. Simultaneous activation of induced heterodimerization between CXCR4 chemokine receptor and cannabinoid receptor 2 (CB2) reveal a mechanism for regulation of tumor progression. J Biol Chem. 2016 Feb 3;pii:jbc.M115.712661. [Epub ahead of print].
   Google Scholar
• Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004;117:927–939.
   PubMed Web of Science ®Google Scholar
• Yang J, Mani SA, Weinberg RA. Exploring a new twist on tumor metastasis. Cancer Res. 2006;66:4549–4552.
   PubMed Web of Science ®Google Scholar
• Laezza C, d’Alessandro A, Malfitano AM, et al. Anandamide inhibits the Wnt/β-catenin signalling pathway in human breast cancer MDA MB 231 cells. Eur J Cancer. 2013;48:3112–3122.
   Web of Science ®Google Scholar
• Tramer MR, Carroll D, Campbell FA, et al. Cannabinoids for control of chemotherapy-induced nausea and vomiting: quantitative systematic review. BMJ. 2001;323:16–21.
   PubMed Web of Science ®Google Scholar
• Khasabova IA, Khasabov S, Paz J, et al. Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy. J Neurosci. 2012;32:7091–7101.
   PubMed Web of Science ®Google Scholar
• Carracedo A, Lorente M, Egia A, et al. The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell. 2006;9:301–312.
   PubMed Web of Science ®Google Scholar
• Molnar J, Szabo D, Pusztai R, et al. Membrane associated antitumor effects of crocine-, ginsenoside- and cannabinoid derivates. Anticancer Res. 2000;20:861–867.
   PubMed Web of Science ®Google Scholar
• Holland ML, Panetta JA, Hoskins JM, et al. The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells. Biochem Pharmacol. 2006;71:1146–1154.
   PubMed Web of Science ®Google Scholar
• Nieri P, Romiti N, Adinolfi B, et al. Modulation of P glycoprotein activity by cannabinoid molecules in HK-2 renal cells. Br J Pharmacol. 2006;148:682–687.
   PubMed Web of Science ®Google Scholar
• McKallip RJ, Lombard C, Martin BR, et al. Delta(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. J Pharmacol Exp Ther. 2002;302:451–465.
   PubMed Web of Science ®Google Scholar
• McKallip RJ, Nagarkatti M, Nagarkatti PS. Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J Immunol. 2005;174:3281–3289.
   PubMed Web of Science ®Google Scholar
• Zhu LX, Sharma S, Stolina M, et al. Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol. 2000;165:373–380.
   PubMed Web of Science ®Google Scholar
• Jorda MA, Verbakel SE, Valk PJ, et al. Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol. Blood. 2002;99:2786–2793.
   PubMed Web of Science ®Google Scholar
• Deveaux V, Cadoudal T, Ichigotani Y, et al. Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS One. 2009;4:e5844.
   PubMed Web of Science ®Google Scholar
• Scott KA, Dalgleish AG, Liu WM. The combination of cannabidiol and Δ9-tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model. Mol Cancer Ther. 2014;13:2955–2967.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay P, Baggelaar M, Erdelyi K, et al. The novel, orally available and peripherally restricted selective cannabinoid CB2 receptor agonist LEI-101 prevents cisplatin-induced nephrotoxicity. Br J Pharmacol. 2016;173:446–458.
   PubMed Web of Science ®Google Scholar
• Bergamaschi MM, Queiroz RH, Zuardi AW, et al. Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf. 2011;6:237–249.
   PubMedGoogle Scholar
• Schlosburg JE, Boger DL, Cravatt BF, et al. Endocannabinoid modulation of scratching response in an acute allergenic model: a new prospective neural therapeutic target for pruritus. J Pharmacol Exp Ther. 2009;329:314–323.
   PubMed Web of Science ®Google Scholar
• Long JZ, Nomura DK, Vann RE, et al. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc Natl Acad Sci U S A. 2009;106:20270–20275.
   PubMed Web of Science ®Google Scholar
• Hawkes N. French drug trial protocol fails to answer key questions. BMJ. 2016;352:i466.
   Google Scholar
• Guzman M, Duarte MJ, Blazquez C, et al. A pilot study of Delta-9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95:1–7.
   PubMed Web of Science ®Google Scholar